BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: Everolimus|DRUG: Everolimus|DRUG: Everolimus|DRUG: Exemestane|DRUG: BI 836845|DRUG: BI 836845|DRUG: Exemestane|DRUG: Exemestane
Sponsor: Boehringer Ingelheim